News Channels

05 Dec 2018 Innovent Receives an Approval from the US FDA to Initiate Clinical Trials for its Anti-OX40 Monoclonal Antibody IBI101
04 Dec 2018 Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program
04 Dec 2018 Triumvira Immunologics Demonstrates Prolonged TAC-T Cell Persistence and Efficacy in Preclinical Models
04 Dec 2018 CARsgen Presents Preliminary Results of CAR-BCMA T Cell Therapy at ASH 2018
04 Dec 2018 ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients
04 Dec 2018 aTyr Pharma Announces Initiation of Phase 1b/2a Study of ATYR1923 in Patients with Pulmonary Sarcoidosis and Collaboration with the Foundation for Sarcoidosis Research (FSR)
04 Dec 2018 Neurelis Announces Acquisition Of Aegis Therapeutics, A Leading Drug Delivery Technology Company
04 Dec 2018 EPIGENE THERAPEUTICS INC. announces presentations on NEO2734, an oral dual inhibitor of both BET and CBP-P300, at the ASH 2018 Congress
04 Dec 2018 Phase 2 cancer study will evaluate T cell-activating immunotherapy MEDI0457 with MedImmune’s durvalumab targeting several HPV-related cancers
04 Dec 2018 Domain Therapeutics signs a multi-target research collaboration and license agreement with Boehringer Ingelheim
04 Dec 2018 Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma
04 Dec 2018 Celgene Corporation Announces Initial Clinical Data from Ongoing Phase 1/2 Evolve Trial with Anti-BCMA CAR T Therapy JCARH125 in Relapsed/Refractory Multiple Myeloma at ASH 2018
04 Dec 2018 NeoImmuneTech Presents Hyleukin-7 and Universal CAR-T Combination Therapy Preclinical Data at ASH Annual Meeting
04 Dec 2018 Alteogen and Lynkogen Expand Agreement to Include Additional Proprietary Fusion Proteins Targeting NASH
04 Dec 2018 Enzo Biochem Reports Publication of Study on Therapeutic Candidate SK1-I Detailing Promising Results in a Model of Treatment-Resistant Breast Cancer
04 Dec 2018 Amphivena Presents at ASH First-in-Human Phase 1 Clinical Data on AMV564
04 Dec 2018 TRIGR Therapeutics Expands Bispecific Immuno-Oncology Pipeline with Exclusive Global License of Clinical Stage, Dual Angiogenesis Inhibitor from ABL Bio
04 Dec 2018 BIVV001 Phase 1/2a Data Presented at ASH Underscore Potential for Once Weekly Dosing with Sustained High Factor Levels in Hemophilia A
04 Dec 2018 Kite Announces Updated Data From ZUMA-3 Study of KTE-X19 in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
04 Dec 2018 Results Presented from Primary Analysis of the Phase III HAVEN 2 Study with Chugai's HEMLIBRA® for Children with Hemophilia A with Inhibitors at the American Society of Hematology 2018

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up